SGLT2 inhibitors lower blood pressure more consistently than GLP-1 drugs, though tirzepatide shows promise | Research

The takeaway

SGLT2 inhibitors consistently lower systolic/diastolic BP by 2.5-4.0/1.5-2.0 mmHg while GLP-1RAs show modest SBP reductions (1.8-5.1 mmHg), though tirzepatide achieves ~10.6 mmHg reduction in select populations.

Tirzepatide: ~10.6 mmHg SBP reduction
Among GLP-1 drugs, tirzepatide stands out with substantially greater blood pressure lowering in select populations

What the researchers found

SGLT2i: SBP -2.5-4.0 mmHg, DBP -1.5-2.0 mmHg, 24h ABPM SBP -3.8 mmHg. GLP-1RA: SBP -1.8-5.1 mmHg, DBP ~0.5 mmHg. Tirzepatide: ~10.6 mmHg SBP in select populations. SGLT2i more consistent; GLP-1RA more variable.

Why it matters

Hypertension is the leading modifiable cardiovascular risk factor, and many hypertensive patients have comorbid diabetes. Understanding the BP-lowering effects of these diabetes drugs helps clinicians make treatment decisions that address both conditions simultaneously.

How the study worked

Narrative review of clinical trial and meta-analysis data on BP effects of SGLT2i and GLP-1RAs.

What this study cannot tell us

Review of heterogeneous data. BP effects vary with patient population, dose, and measurement method. Not designed as primary antihypertensives. Tirzepatide data limited.

How to read the evidence

Narrative review of clinical trial data. Provides useful clinical comparison but not systematic or meta-analytic.

When this study was published

Published in 2025.

The bigger picture

As diabetes medications increasingly demonstrate cardiovascular benefits, their BP-lowering effects add another dimension to treatment selection. The remarkable tirzepatide BP reduction may reflect its dual GLP-1/GIP mechanism or greater weight loss.

Questions still open

Why does tirzepatide lower BP more than other GLP-1 drugs?
Could these drugs replace one antihypertensive in patients with diabetes?
Is the BP reduction sufficient to improve cardiovascular outcomes independently?

Common questions

Do diabetes drugs lower blood pressure?

Yes. SGLT2 inhibitors consistently reduce blood pressure by 2.5-4.0 mmHg (systolic) through a mild diuretic effect. GLP-1 drugs have more modest effects (1.8-5.1 mmHg), though tirzepatide can lower it by about 10.6 mmHg in some patients. Neither replaces standard blood pressure medications but can be helpful additions.

Which diabetes drug lowers blood pressure most?

Among the two classes, SGLT2 inhibitors are more reliable for consistent BP reduction. However, tirzepatide (a dual GLP-1/GIP agonist) has shown the largest single-agent BP reduction (~10.6 mmHg) in select populations, likely related to its greater weight loss effect.

Read the original research

Blood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists.

Current hypertension reports, 27(1), 28

View on PubMed ↗Publisher’s paper ↗

Citation

Siddiqi, Ahmed Kamal; Khan, Muhammad Shahzeb; Kulkarni, Anandita; Hall, Michael E; Böhm, Michael; Díez, Javier; Butler, Javed. (2025). Blood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists.. Current hypertension reports, 27(1), 28. https://doi.org/10.1007/s11906-025-01342-7